New Neoadjuvant Bladder Cancer Therapy Data

THE FDA expands approval of chemo-free bladder cancer combo in curative setting as a new meta-analysis evaluates therapeutic efficacy. This systemic review evaluated 15 prospective phase two or higher clinical trials encompassing 1,545 patients with muscle-invasive bladder cancer to assess three perioperative strategies. Investigators directly compared enfortumab vedotin monotherapy, enfortumab vedotin plus pembrolizumab, and various immune checkpoint inhibitor combinations. The primary endpoint analyzed across these distinct cohorts was the pathological complete response rate.

Evaluating Neoadjuvant Bladder Cancer Therapy Efficacy

The combination of enfortumab vedotin and pembrolizumab demonstrated the highest clinical efficacy, achieving an observed pathological complete response rate of 57 percent. In comparison, alternative immune checkpoint inhibitor regimens achieved a 37 percent pooled response rate, while enfortumab vedotin monotherapy resulted in a 36 percent response rate. The clinical superiority of the combination protocol over checkpoint inhibition alone reached strong statistical significance.

Outcomes in Cisplatin Ineligible Patients

For individuals deemed ineligible for standard cisplatin chemotherapy, the combination treatment maintained its profound therapeutic benefit. Within this specific subgroup, the combination strategy produced a 57 percent response rate, significantly outperforming the 29 percent rate observed with standard immune checkpoint inhibitors. Surgical feasibility also remained exceptionally high across the evaluated arms, with a pooled radical cystectomy completion rate of 89 percent.

Data extracted from the phase three EV-303 trial revealed substantial survival benefits for patients receiving the combination protocol compared to surgery alone. The regimen reduced the risk of event-free survival events by 60 percent, yielding a hazard ratio of 0.40, and decreased the overall mortality risk by 50 percent with a hazard ratio of 0.50. Meanwhile, the NIAGARA trial reported hazard ratios of 0.68 for event-free survival and 0.75 for overall survival. While cross-trial variations limit direct statistical pooling, these findings indicate that this combination serves as a highly effective perioperative strategy for individuals who cannot tolerate cisplatin. Clinicians should consider these robust pathological responses and survival advantages when designing personalized treatment pathways for advanced urothelial malignancies.

Reference

Yajima S et al. Enfortumab vedotin monotherapy, enfortumab vedotin plus pembrolizumab, and immune checkpoint inhibitor-based neoadjuvant therapy for muscle-invasive bladder cancer: A systematic review and meta-analysis. Urol Oncol. 2026. DOI: 10.1016/j.urolonc.2026.06.009.

Featured Image: Kansuda on Adobe Stock.